STRATA Skin Sciences, Inc. (SSKN) Q2 2024 Earnings Call Transcript Summary
STRATA Skin Sciences, Inc. (SSKN) Q2 2024 Earnings Call Transcript Summary
Gross profit increased to $4.9 million with a gross The following is a summary of the STRATA Skin Sciences, Inc. (SSKN) Q2 2024 Earnings Call Transcript:
以下是STRATA Skin Sciences, Inc. (SSKN) 2024年Q2業績會的簡要摘要：
Financial Performance:
金融業績：
STRATA reported Q2 2024 total revenue of $8.4 million, up 2% year-over-year.
Net loss from operations improved, decreasing by $1.5 million to approximately $500,000.
Gross profit increased to $4.9 million with a gross margin of 58.5%, up from 52.3% in Q2 2023.
Equipment revenue grew 11% year-over-year to $3.1 million, driven by strategic redeployment of XTRAC devices.
STRATA報告2024年Q2總營業收入840萬美元，同比增長2%。
營業淨虧損得到改善，減少了150萬，約爲50萬美元。
毛利潤增加至490萬美元，毛利率爲58.5%，高於2023年Q2的52.3%。
設備收入同比增長11%，達到310萬美元，主要受XTRAC設備的戰略再部署推動。
Business Progress:
業務進展：
Expanded Direct-To-Consumer (DTC) marketing from four to 28 areas nationally, decreasing cost per lead and appointment, and growing patient appointments for XTRAC treatments.
Reduced total operating expenses by approximately $860,000 or 14% year-over-year.
Continued efforts to optimize XTRAC device deployment, reducing the installed base from 907 to 881 units to enhance utilization rates and equipment revenue.
Growing TheraClearX device installations for acne treatment, with an increase to 117 devices.
擴大直銷營銷（DTC）範圍，從4個區域擴展到全國28個區域，降低每個患者的成本和預約，促進XTRAC治療患者的預約量增長。
營業費用總額同比減少約860,000美元或14%。
繼續努力優化XTRAC設備部署，將安裝基數從907個減少到881個，以提高利用率和設備收入。
TheraClearX設備的安裝量用於痤瘡治療有所增加，達到117台。
Opportunities:
機會：
Increased focus on DTC marketing is likely to continue enhancing patient awareness and appointments for XTRAC treatments in more areas.
Strategic redeployment of XTRAC devices expected to improve procedural volume and equipment revenue further.
Expansion of TheraClearX devices in national dermatology clinic groups and high acne volume accounts offers a significant opportunity in the acne treatment market.
進一步加大DTC營銷的重點，很可能會進一步提高患者對XTRAC治療的認知和預約量。
XTRAC設備戰略再部署預計將進一步提高手術量和設備收入。
在全國皮膚科診所集團和高痤瘡發病率機構擴大TheraClearX設備的使用具有重大機會，聲音顯著。
Risks:
風險：
Decline in gross domestic recurring billing by 6% year-over-year, continuing from a 3% decline in Q1 following a trend of more significant declines in previous years.
國內經常性賬單淨額同比下降6%，繼續Q1的3%下降趨勢，這是近年來更大程度下降的趨勢。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。